Xglip 20mg Tablet contains Teneligliptin 20mg, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor used in the management of type 2 diabetes mellitus. By inhibiting the DPP-4 enzyme, Teneligliptin enhances the levels of incretin hormones, which increase insulin secretion and decrease glucagon release in a glucose-dependent manner, thereby improving glycemic control. Xglip is indicated as an adjunct to diet and exercise to improve glycemic parameters in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. The 20mg dosage provides effective glycemic regulation with a favorable safety profile, demonstrating minimal risk of hypoglycemia when used appropriately. Teneligliptin is characterized by its long half-life, allowing once-daily dosing, which enhances patient compliance. It is well tolerated, with common adverse effects including mild gastrointestinal disturbances and nasopharyngitis. Renal dose adjustment is not typically required, making it suitable for patients with varying degrees of renal impairment. Xglip 20mg Tablet should be used under medical supervision, with regular monitoring of blood glucose levels to optimize therapeutic outcomes and minimize potential adverse effects.